Status:
COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma
Lead Sponsor:
Xiangya Hospital of Central South University
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine whether an EBV-LMP1 targeted DNAzyme is effective in radiosensitization of nasopharyngeal carcinoma in combination with standard radiation therapy.
Detailed Description
INTRODUCTION Nasopharyngeal carcinoma (NPC) is a serious health problems worldwide, particularly in the southern Chinese population, with an incidence rate ranging from 15 to 50 per 100 000. NPC is an...
Eligibility Criteria
Inclusion
- Clinical diagnosis of nasopharyngeal squamous carcinoma
- EBV-LMP1 positive
- Signed Informed Consent Form
Exclusion
- Abnormal laboratory results within 45 days prior to study entry
- Participation in any study involving an experimental drug or an experimental medical device in 30 days prior to study entry
- Current pregnancy
- Inability to provide informed consent
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01449942
Start Date
May 1 2009
End Date
September 1 2011
Last Update
October 10 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
XiangYa Hospital, Central South University
Changsha, Hunan, China, 410078